{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+3&page=22",
    "query": {
      "intervention": "Dose level 3",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 17830,
    "total_pages": 1783,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+3&page=23&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+3&page=21&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-14T23:30:25.984Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01386385",
      "title": "Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lung Adenocarcinoma",
        "Lung Adenocarcinoma, Mixed Subtype",
        "Lung Large Cell Carcinoma",
        "Lung Squamous Cell Carcinoma",
        "Minimally Invasive Lung Adenocarcinoma",
        "Stage III Lung Non-Small Cell Cancer AJCC v7",
        "Stage IIIA Lung Non-Small Cell Cancer AJCC v7",
        "Stage IIIB Lung Non-Small Cell Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "3-Dimensional Conformal Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        },
        {
          "name": "Veliparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2011-06-20",
      "completion_date": "2026-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-11-13",
      "last_synced_at": "2026-11-14T23:30:25.984Z",
      "location_count": 232,
      "location_summary": "Anchorage, Alaska • Tucson, Arizona • Beverly Hills, California + 158 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01386385"
    },
    {
      "nct_id": "NCT00665925",
      "title": "Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Fostamatinib disodium (R935788)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rigel Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 457,
      "start_date": "2008-05",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2016-09-16",
      "last_synced_at": "2026-11-14T23:30:25.984Z",
      "location_count": 24,
      "location_summary": "La Jolla, California • Palm Desert, California • Hamden, Connecticut + 21 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Hamden",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainsville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00665925"
    },
    {
      "nct_id": "NCT02039817",
      "title": "PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Impairment",
        "Renal Insufficiency",
        "Kidney Disease",
        "Kidney Diseases"
      ],
      "interventions": [
        {
          "name": "IDN-6556",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Conatus Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 16,
      "start_date": "2014-01",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2016-01-28",
      "last_synced_at": "2026-11-14T23:30:25.984Z",
      "location_count": 2,
      "location_summary": "DeLand, Florida • Miami, Florida",
      "locations": [
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02039817"
    },
    {
      "nct_id": "NCT00667017",
      "title": "RFT5-dgA Immunotoxin in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "RFT5-dgA immunotoxin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "fluorescence activated cell sorting",
          "type": "OTHER"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 1,
      "start_date": "2008-11-07",
      "completion_date": "2010-02",
      "has_results": true,
      "last_update_posted_date": "2018-12-14",
      "last_synced_at": "2026-11-14T23:30:25.984Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00667017"
    },
    {
      "nct_id": "NCT05158140",
      "title": "Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumococcal Infection"
      ],
      "interventions": [
        {
          "name": "V110",
          "type": "BIOLOGICAL"
        },
        {
          "name": "V114",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for V110",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for V114",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 850,
      "start_date": "2022-01-12",
      "completion_date": "2023-02-21",
      "has_results": true,
      "last_update_posted_date": "2025-07-18",
      "last_synced_at": "2026-11-14T23:30:25.984Z",
      "location_count": 42,
      "location_summary": "North Hollywood, California • Northridge, California • Paramount, California + 38 more",
      "locations": [
        {
          "city": "North Hollywood",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Paramount",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05158140"
    },
    {
      "nct_id": "NCT01906489",
      "title": "20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anemia",
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "AKB-6548",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Akebia Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "82 Years",
        "sex": "ALL",
        "summary": "18 Years to 82 Years"
      },
      "enrollment_count": 210,
      "start_date": "2013-07-23",
      "completion_date": "2014-09-03",
      "has_results": true,
      "last_update_posted_date": "2022-07-21",
      "last_synced_at": "2026-11-14T23:30:25.984Z",
      "location_count": 47,
      "location_summary": "Glendale, Arizona • Tucson, Arizona • Azusa, California + 44 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Downey",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01906489"
    },
    {
      "nct_id": "NCT07552558",
      "title": "Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma",
        "HPV-Negative Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Hypofractionated Stereotactic Body Radiotherapy (SBRT)",
          "type": "RADIATION"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ficerafusp alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2026-11-30",
      "completion_date": "2034-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-14T23:30:25.984Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07552558"
    },
    {
      "nct_id": "NCT03565315",
      "title": "Phase I Study to Evaluate a Human Monoclonal Antibody (MAb) 10E8VLS Administered Alone or Concurrently With MAb VRC07-523LS Via Subcutaneous Injection in Healthy Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Adult Immune Response"
      ],
      "interventions": [
        {
          "name": "VRC-HIVMAB095-00-AB (10E8VLS)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VRC-HIVMAB075-00-AB (VRC07-523LS)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 9,
      "start_date": "2018-07-10",
      "completion_date": "2019-03-04",
      "has_results": true,
      "last_update_posted_date": "2020-12-30",
      "last_synced_at": "2026-11-14T23:30:25.984Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03565315"
    },
    {
      "nct_id": "NCT03575325",
      "title": "Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoid Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Refractory Acute Lymphoblastic Leukemia",
        "Relapsed Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "CPX-351",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2018-10-11",
      "completion_date": "2023-09-14",
      "has_results": true,
      "last_update_posted_date": "2024-12-12",
      "last_synced_at": "2026-11-14T23:30:25.984Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03575325"
    },
    {
      "nct_id": "NCT02361489",
      "title": "Clinical Study to Compare Various Dosing and Titration Guidelines of Insulin Delivered Via V-Go ® in Patients With Type 2 Diabetes Initiating Basal Bolus Therapy in Primary Care Offices",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Type II"
      ],
      "interventions": [
        {
          "name": "V-Go",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Valeritas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "21 Years to 80 Years"
      },
      "enrollment_count": 90,
      "start_date": "2015-02",
      "completion_date": "2016-04",
      "has_results": false,
      "last_update_posted_date": "2015-02-11",
      "last_synced_at": "2026-11-14T23:30:25.984Z",
      "location_count": 1,
      "location_summary": "Wilkes-Barre, Pennsylvania",
      "locations": [
        {
          "city": "Wilkes-Barre",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02361489"
    }
  ]
}